Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraTect-KRAS and AccuraTect-BRAF that are companion diagnostics for colorectal cancer; AccuraTect-EGFR, a companion diagnostic for lung cancer; and AccuraDTect SARS-CoV-2 RT-qPCR kits, as well as test providers. Genomictree Inc. was founded in 2000 and is headquartered in Daejeon, South Korea.
Stock data | 2024 | Change |
---|---|---|
Price | $15.93 | N/A |
Market Cap | $0 | N/A |
Employees | 81.00 | N/A |